| 8.795 0.035 (0.4%) | 12-05 10:01 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 12.04 | 1-year : | 14.23 |
| Resists | First : | 10.31 | Second : | 12.18 |
| Pivot price | 10.19  |
|||
| Supports | First : | 7.26 | Second : | 6.04 |
| MAs | MA(5) : | 9.08 |
MA(20) : | 9.67 |
| MA(100) : | 8.19 |
MA(250) : | 0 | |
| MACD | MACD : | 0.1 |
Signal : | 0.3 |
| %K %D | K(14,3) : | 16.4 |
D(3) : | 25.2 |
| RSI | RSI(14): 43 |
|||
| 52-week | High : | 12.18 | Low : | 2.31 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ FULC ] has closed above bottom band by 19.6%. Bollinger Bands are 111.8% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 20 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 9.32 - 9.37 | 9.37 - 9.41 |
| Low: | 8.56 - 8.63 | 8.63 - 8.69 |
| Close: | 8.66 - 8.76 | 8.76 - 8.85 |
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy; and FTX-6058, an investigational oral fetal hemoglobin inducer for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has research and discovery collaboration agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and has a strategic collaboration and license agreement with MyoKardia, Inc. to discover, develop, and commercialize novel targeted therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Thu, 04 Dec 2025
Fulcrum Therapeutics (NASDAQ:FULC) Stock Price Up 7.7% - Here's What Happened - MarketBeat
Tue, 02 Dec 2025
Fulcrum Therapeutics (Nasdaq: FULC) to review new PIONEER sickle cell data on Dec. 7 - Stock Titan
Sat, 29 Nov 2025
Fulcrum Therapeutics (NASDAQ:FULC) Trading Down 4.6% - Here's What Happened - MarketBeat
Mon, 24 Nov 2025
Truist Securities Initiates Coverage of Fulcrum Therapeutics (FULC) with Buy Recommendation - Nasdaq
Mon, 24 Nov 2025
FULC Stock Boosted: HC Wainwright & Co. Raises Price Target to $ - GuruFocus
Mon, 17 Nov 2025
Fulcrum Therapeutics (FULC) Price Target Increased by 11.55% to 13.90 - Nasdaq
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 54 (M) |
| Shares Float | 28 (M) |
| Held by Insiders | 1.5 (%) |
| Held by Institutions | 99.9 (%) |
| Shares Short | 3,560 (K) |
| Shares Short P.Month | 3,550 (K) |
| EPS | -1.14 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.67 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -20.7 % |
| Return on Equity (ttm) | -31.3 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | -0.97 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.48 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -60 (M) |
| Levered Free Cash Flow | -36 (M) |
| PE Ratio | -7.73 |
| PEG Ratio | 0 |
| Price to Book value | 2.39 |
| Price to Sales | 0 |
| Price to Cash Flow | -7.94 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|